Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Zanubrutinib + Obinutuzumab vs. Obinutuzumab in Patients With R/R FL - Updated Analysis of the ROSEWOOD Study"

508 views
June 9, 2023
Comments 0
Login to view comments. Click here to Login